Currently, the pembrolizumab (anti-PD-1) is approved for use as first- and second- line therapy in patients with advanced NSCLC whose tumors express PD-L1 in immunohistochemistry analysis (10, 13). Here, PDCD1 is linked to non-small cell lung carcinoma.